Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (DH) lymphomas harboring rearrangements of the MYC and BCL-2 oncogenes, which enrich for a patient's population characterized by refractoriness to anthracycline-based chemotherapy. Here we hypothesized that adaptive mechanisms to MYC-induced replicative and oxidative stress, consisting in DNA damage response (DDR) activation and BCL-2 overexpression, could represent the biologic basis of the poor prognosis and chemoresistance observed in MYC/BCL-2-positive lymphoma. We first integrated targeted gene expression profiling (T-GEP), fluorescence in situ hybridization (FISH) analysis, and characterization of replicative and oxidative stress biomarkers in two independent DLBCL cohorts. The presence of oxidative DNA damage biomarkers identified a poor prognosis double expresser (DE)-DLBCL subset, characterized by relatively higher BCL-2 gene expression levels and enrichment for DH lymphomas. Based on these findings, we tested therapeutic strategies based on combined DDR and BCL-2 inhibition, confirming efficacy and synergistic interactions in in vitro and in vivo DH-DLBCL models. These data provide the rationale for precision-therapy strategies based on combined DDR and BCL-2 inhibition in DH or DE-DLBCL.
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma / A. Rossi, S. Orecchioni, P. Falvo, V. Tabanelli, E. Baiardi, C. Agostinelli, F. Melle, G. Motta, A. Calleri, S. Fiori, C. Corsini, B. Casadei, S. Mazzara, U. Vitolo, F. Bertolini, P.L. Zinzani, M. Alcalay, P.G. Pelicci, S. Pileri, C. Tarella, E. Derenzini. - In: LEUKEMIA. - ISSN 0887-6924. - (2021). [Epub ahead of print] [10.1038/s41375-021-01347-6]
|Titolo:||Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2021|
|Data ahead of print / Data di stampa:||24-lug-2021|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1038/s41375-021-01347-6|
|Appare nelle tipologie:||01 - Articolo su periodico|